T
Todd R. Golub
Researcher at Harvard University
Publications - 454
Citations - 234100
Todd R. Golub is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Gene expression profiling. The author has an hindex of 164, co-authored 422 publications receiving 201457 citations. Previous affiliations of Todd R. Golub include Rush University Medical Center & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
TEL is one of the targets for deletion on 12p in many cases of childhood B-lineage acute lymphoblastic leukemia
Seisho Takeuchi,T Seriu,Claus R. Bartram,Todd R. Golub,A Reiter,Isao Miyoshi,D G Gilliland,H P Koeffler +7 more
TL;DR: It is emphasized the importance of loss of the normal TEL allele in childhood precursor B-lineage ALL, which has qualities of a tumor suppressor-like function.
Patent
Methods and products related to drug screening using gene expression patterns
TL;DR: In this paper, high-throughput methods for identifying properties of cells under a variety of cellular conditions are described. But the methods are not suitable for the detection of cellular modulators.
Journal ArticleDOI
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Eliezer M. Van Allen,Eliezer M. Van Allen,Vivian Wai Yan Lui,Vivian Wai Yan Lui,Ann Marie Egloff,Eva M. Goetz,Hua Li,Jonas T. Johnson,Umamaheswar Duvvuri,Julie E. Bauman,Nicolas Stransky,Yan Zeng,Breean R. Gilbert,Kelsey P. Pendleton,Lin Wang,Simion I. Chiosea,Carrie Sougnez,Nikhil Wagle,Nikhil Wagle,Fan Zhang,Yu Du,David A Close,Paul A. Johnston,Aaron McKenna,Scott L. Carter,Todd R. Golub,Todd R. Golub,Gad Getz,Gad Getz,Gordon B. Mills,Levi A. Garraway,Levi A. Garraway,Jennifer R. Grandis +32 more
TL;DR: Selective erlotinib use in HNSCC may be informed by precision oncology approaches and Hypotheses were formulated regarding enhanced erlot inib response in preclinical models harboring the patient tumor somatic variant MAPK1 E322K following the identification of tumor somatics variants.
Journal ArticleDOI
Corrections: miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells
Eric R. Lechman,Bernhard Gentner,Stanley W.K. Ng,Erwin M. Schoof,Peter van Galen,James A. Kennedy,Silvia Nucera,Fabio Ciceri,Kerstin B. Kaufmann,Naoya Takayama,Stephanie M. Dobson,Aaron Trotman-Grant,Gabriela Krivdova,Janneke Elzinga,Amanda Mitchell,Björn Nilsson,Karin G. Hermans,Kolja Eppert,Rene Marke,Ruth Isserlin,Veronique Voisin,Gary D. Bader,Peter W. Zandstra,Todd R. Golub,Benjamin L. Ebert,Jun Lu,Mark D. Minden,Jean C.Y. Wang,Luigi Naldini,John E. Dick +29 more
Journal ArticleDOI
The Connectivity Map Links Iron Regulatory Protein-1–Mediated Inhibition of Hypoxia-Inducible Factor-2a Translation to the Anti-inflammatory 15-deoxy-Δ12,14-Prostaglandin J2
Michael Zimmer,Justin Lamb,Benjamin L. Ebert,Mary Lynch,Christopher Neil,Emmett V. Schmidt,Todd R. Golub,Othon Iliopoulos +7 more
TL;DR: In this paper, the authors showed that PGJ2 (15-deoxy-Δ12,14-prostaglandin J2) can inhibit the translation of the HIF2a message in a mammalian target of rapamycin-independent manner by promoting the binding of iron regulatory protein-1 (IRP1) to a noncanonical iron responsive element (IRE) embedded within the 5′-untranslated region of HIF 2a message.